Analysts Maintain Buy Ratings on Granules India with Positive 1QFY27 Results
Granules India reported steady growth in 1QFY27, with consistent year-on-year earnings increases over five quarters. Motilal Oswal noted in-line revenue and EBITDA, highlighting the ramp-up of the CDMO business despite a minor EBITDA loss due to project changes. Emkay Global Financial observed EBITDA and gross margin beats, driven by a favorable product mix and increased complex generics sales. Both firms maintain a BUY rating, with target prices of Rs 1,010 and Rs 950 respectively, citing positive outlooks including facility utilization and free cash flow generation.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 30/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 22 Jul, 07:15 am. Other outlets followed.
- 1